Ascendis Pharma (ASND) Reports Q2 EPS by EUR (1.46)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Ascendis Pharma (ASND) Reports Q2 EPS by EUR (1.46)

Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results

August 10, 2022 4:01 PM EDT

  U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022

  SKYTROFA revenue continued to double quarter-to-quarter, reaching 4.4 million in the second quarter

  With anticipated growth in U.S. revenues and approximately 1 billion of cash, cash equivalents, and marketable securities on hand, Ascendis is positioned to fulfill Vision 3x3 and become cash flow positive

  Conference call today at 4:30 pm ET

COPENHAGEN, Denmark, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:... More